Afzelin

Afzelin

SCHEMBL1689477

C[C@@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 1.00
P4HB P07237 6/20 0.85
L3MBTL1 Q9Y468 4/20 0.85
XDH P47989 3/20 0.85
SLCO2B1 O94956 3/20 0.85
AKR1B1 P15121 2/20 0.85
MAOA P21397 2/20 0.85
EPHX2 P34913 2/20 0.85
PIM2 Q9P1W9 2/20 0.85
KDM4E B2RXH2 2/20 0.85
ALDH1A1 P00352 2/20 0.85
CA12 O43570 1/20 0.85
CA2 P00918 1/20 0.85
CA4 P22748 1/20 0.85
CA7 P43166 1/20 0.85
POLB P06746 3/20 0.83
GAA P10253 3/20 0.83
RECQL P46063 2/20 0.83
APEX1 P27695 1/20 0.83
MAPT P10636 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Afzelin SCHEMBL1689483 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL29366762 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL15966975 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL12691631 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL14690855 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL571131 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL3807411 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Kaempferol-3-O-Rhamnoside SCHEMBL15917403 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL15918354 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1
Afzelin SCHEMBL15517458 1.00 NQO2 (1.00) NQO2P4HBL3MBTL1XDHSLCO2B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743181-A1 POLYPHENOL-RICH DAMASK ROSE EXTRACT DERIVED FROM A HYDRODISTILLATION BYPRODUCT AND ITS USES AS A FOOD SUPPLEMENT Robertet S.A. (FR) 2026-05-20 EP claimed
EP-4691473-A1 PLATYCLADUS ORIENTALIS EXTRACT, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Academy of TCM Beauty Supplements Co., Ltd. (CN) 2026-02-11 EP claimed
US-12311001-B2 Use of extracellular vesicles of Rhizoma Drynariae in preparation of medicine for treating orthopedic diseases The Third Affiliated Hospital of Guangzhou University of Chinese Medicine (CN) 2025-05-27 US claimed
WO-2025011789-A1 POLYPHENOL-RICH DAMASK ROSE EXTRACT DERIVED FROM A HYDRODISTILLATION BYPRODUCT AND ITS USES AS A FOOD SUPPLEMENT ROBERTET S.A. (FR) 2025-01-16 WO claimed
US-20250000923-A1 USE OF EXTRACELLULAR VESICLES OF RHIZOMA DRYNARIAE IN PREPARATION OF MEDICINE FOR TREATING ORTHOPEDIC DISEASES The Third Affiliated Hospital of Guangzhou University of Chinese Medicine (CN) 2025-01-02 US claimed
US-20240325484-A1 COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT ANGIOLAB, INC. (KR) 2024-10-03 US claimed
EP-4395802-A1 COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT ANGIOLAB., INC. (KR) 2024-07-10 EP claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
CN-113552242-B Method for constructing Chinese rose fingerprint, detection method and content determination method 广东一方制药有限公司 2023-04-07 CN claimed
WO-2023038480-A1 COMPOSITION, FOR PREVENTING, TREATING OR RELIEVING INFLUENZA VIRUS INFECTION, COMPRISING MIXTURE OF AGRIMONIA PILOSA EXTRACT AND GALLA RHOIS EXTRACT AS ACTIVE INGREDIENT 에이피알지 주식회사 2023-03-16 WO claimed
US-20120010146-A1 COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER HANCOCK JAFFE LABORATORIES, INC. (US) 2012-01-12 US claimed
US-7763287-B2 Extract of Cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement HANKOOK PHARM. CO., INC. (KR) 2010-07-27 US claimed
WO-2010053918-A1 COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER HANCOCK JAFFE LABORATORIES, INC. (US) 2010-05-14 WO claimed
CN-100574744-C Have the extract of the Chinese cercis of antioxidant activity and activity of fighting against senium, and contain this extract and be used for the protection of antioxidation, skin aging and improve the cosmetic composition of wrinkle HANKOOK PHARM CO INC 2009-12-30 CN claimed
US-20080187610-A1 EXTRACT OF CERCIS CHINENSIS HAVING ANTI-OXIDANT ACTIVITY AND ANTI-AGING ACTIVITY, AND COSMETICAL COMPOSITION CONTAINING THE EXTRACT FOR ANTI-OXIDATION, SKIN-AGING PROTECTION AND WRINKLE IMPROVEMENT HANKOOK PHARM. CO., INC. (KR) 2008-08-07 US claimed
US-7176239-B2 Methods and compositions for treatment of Ataxia-telangeictasia Wang, Suming (US) 2007-02-13 US claimed
US-20060078633-A1 Extract of cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement HANSAENG COSMETIC CO., LTD. (KR) 2006-04-13 US claimed
CN-1731978-A Extract of cercis chinensis having antioxidant and anti-aging activities, and cosmetic composition containing the same for preventing oxidation, preventing skin aging and improving wrinkles HANKOOK PHARM CO INC (KR) 2006-02-08 CN claimed
US-20050009760-A1 Methods and compositions for treatment of ataxia-telangeictasia WANG, SUMING 2005-01-13 US claimed
WO-2004058213-A1 EXTRACT OF CERCIS CHINENSIS HAVING ANTI-OXIDANT ACTIVITY AND ANTI-AGING ACTIVITY, AND COSMETICAL COMPOSITION CONTAINING THE EXTRACT FOR ANTI-OXIDATION, SKIN-AGING PROTECTION AND WRINKLE IMPROVEMENT HANKOOK PHARM. CO., INC. (KR) 2004-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060078633-A1 Extract of cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement POT1, TERT, TERF2 NQO2 2926/4885P4HB 3745/4885L3MBTL1 2173/4885
US-20080187610-A1 EXTRACT OF CERCIS CHINENSIS HAVING ANTI-OXIDANT ACTIVITY AND ANTI-AGING ACTIVITY, AND COSMETICAL COMPOSITION CONTAINING THE EXTRACT FOR ANTI-OXIDATION, SKIN-AGING PROTECTION AND WRINKLE IMPROVEMENT POT1, TERT, TERF2 NQO2 2882/4885P4HB 3882/4885L3MBTL1 2201/4885
US-20240325484-A1 COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT PRUNE1, HDLBP, CROCC NQO2 680/4885P4HB 3715/4885L3MBTL1 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.